MESO Q2 2022 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+6.5% YoY

Gross Profit

-$14M-604.8% margin

Operating Income

-$22M-932.8% margin

Net Income

-$26M-1089.2% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

-33.7%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$704M

Total Liabilities

$169M

Stockholders' Equity

$536M

Cash & Equivalents

$94M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+6.5%
Gross Profit	-$14M	-$18M	+21.9%
Operating Income	-$22M	-$26M	+15.6%
Net Income	-$26M	-$26M	-1.0%